BLB International Company Limited signed an agreement to acquire 11.37% stake in China Regenerative Medicine International Limited (SEHK:8158) from All Favour Holdings Limited for HKD 360 million on January 24, 2018. BLB International Company Limited will acquire 2 billion shares of China Regenerative Medicine International Limited. Post completion BLB International Company Limited will hold 11.37% stake where as All Favour Holdings Limited will hold 18.53% stake in China Regenerative Medicine International Limited. The transaction is approved by the Board of Baolingbao Biology Co., Ltd. on January 24, 2018. On April 29, 2019, Baolingbao Biology Co.,Ltd. held its 4th directorate’s 17th meeting and approved the decision to terminate the transaction. BLB International Company Limited and All Favour Holdings Limited signed the termination agreement for the sale and purchase of China Regenerative Medicine International Limited’s shares. This termination matter is still subject to approval from the Baolingbao Biology Co.,Ltd.'s shareholders. BLB International Company Limited cancelled the acquisition of 11.37% stake in China Regenerative Medicine International Limited (SEHK:8158) from All Favour Holdings Limited on October 30, 2019.